Markup | Genome Research

Table 1.

PCR Conditions for Amplifying 68 Equine Type I Loci with Universal Primers

Hsa	UCD	Symbol	Locus name	Anl T. °C	MgCl (mm)	R.E.	Size (bp)	Accession no.[ii]
1p36.2	2	NPPA	natriuretic peptide precursor A	50	2	HinfI	305	AF134229
1p13.1	5	NGFB	nerve growth factor, β	53	2.5	RsaI	158	AF134228
1q21	5	GBA	glucosidase, β acid	53	2	RsaI	345	AF134220
1q23–q25.1	5	AT3	antithrombin III	55	2	—	187	AF134055
1q31	5	LAMC1	laminin, C-1	50	2	—	∼1400	AF134225, 6
2p21	15	SPTBN1[iii]	spectrin, β, nonerythrocytic 1	50	2	—	975	AF130782
2q12–q14	15	PAX8	paired box homeotic gene 8	55	2	HaeIII	147	AF130778
2q14	15	IL1b[iv] [v]	interleukin-1 β	55	1	HindIII	∼906	AF130767, 8
2q24–q32	18	CHRNA	cholinergic receptor, nicotinic, α	58	1	—	405	AF130750
2q31–q32	18	NEB	nebulin	56	1	PvuII	∼2000	AF130774, 5
2q33–q34	D	CHRNG	cholinergic receptor, nicotinic, γ	60	1	—	264	AF130751
2q34	D	FN1	fibronectin 1	55	2	—	1009	AF130764
3p24.3–p24.2	16	RARB	retonic acid receptor, β	55	3	CfoI	208	AF13424
3p21.33	16	GLB1 [iii]	galactosidase, β-1	50	2	RsaI	429	AF130765
3q21–q24	16	CP	ceruloplasmin	55	2.5	—	∼1500	AF134057
3q21–q24	16	RHO [iii]	rhodopsin	55	2	RsaI	327	AF130780
3q28	19	SST[vi]	somatostatin	50	1	—	931	AF130783
4q22	3	ADH2	alcohol dehydrogenase 2	52	1	—	295	AF133272
4q22	3	ADH3	alcohol dehydrogenase 3	52	2	—	>2000	AF134056
4q28	2	FGG	fibrinogen, γ polypeptide	53	2	—	∼1100	AF134218, 9
5q32–q34	14	ADRB2	adrenergic receptor, β-2	55	2	HinfI	354	AF130746
6p24–p23	20	EDNI[iii]	endothelin-1	58	2	—	266	AF130760
6q13	20	COL9a1[iii]	collagen, type IX, α-1	50	2	—	292	AF130755
6q21.1–q23	10	CGA	chorionic gonadotropin, α chain	45	4	—	242	AF130749
6q21–q22.3	10	COL10[iii]	collagen, type X, α 1	50	2	PVuII	365	AF130754
6q25.3	14	SOD2ps[viii]	superoxide dismutase 2	55	2	—	154	AF130781
7p15–p14	4	TCRG	t cell antigen receptor, γ subunit	42	2.5	HinfI	252	AF134235
7q11.2	13	ELN[iii]	elastin	58	1	—	263	AF130761
7q21.11	13	GUSB	glucuronidase β	53	2	Sau3AI	382	AF134223
7q36	4	EN2	Engrailed 2	53	2	PvuII	189	AF134060
8q24.2–q24.3	9	TG	thyroglobulin	58	1	—	749	AF130785
9p22	23	IFNA1	interferon, α-1	53	2	PvuII	373	AF135017
9p21	23	IFNB1	interferon, β-1	55	2	HaeIII	450	AF134227
9p13	23	CNTFR	ciliary neurotrophic f. recept.	57	2.5	—	456	AF134058
9q31	25	TXN	thioredoxin	55	2	HinfI	∼780	AF134237
9q34	25	GRP78	glucose-regulated protein	55	2	PvuII	∼740	AF134222
10p13	29	VIM	vimentin	57	2	—	∼1230	AF135018
11p15.5	7	HBB	hemoglobin, β	50	2.5	—	171	AF134224
11p15.3–p15.1	7	PTH	parathyroid hormone	55	2	—	311	AF134233
11cen–q13	12	ADRBK1	adrenergic receptor β kinase I	53	1	—	328	AF134059
11q13	12	CD20[iii]	CD20 antigen	55	2	—	1007	AF130748
11q23	7	DRD2	dopamine receptor D2	50	2.5	—	∼1300	AF134061, 2
11q23.3	7	THY1	Thy-1 T-cell surface antigen	50	2	—	∼800	AF134236
12p12.1	9	KRAS2ps[viii]	Kirsten murine sarc. 2 viral onc., ps.	58	1	—	329	AF130769
12q13.3	D	PFKM	phosphofructokinase m	60	2	—	∼1600	AF134230, 1
12q14	D	IFNG	Interferon γ	45	2	—	325	AF130766
12q24.2	6	TCF1	transcription factor 1	58	1	—	602	AF130784
13q14.1q–14.2	17	RB1[vii]	retinoblastoma	55	2	—	705	AF130779
14q11.2	1	CHY[iii]	chymase- mast cell	58	2	—	697	AF130752
14q12	1	MYH6[v]	myosin, heavy pol. 6 &/or 7, see text	58	2	RsaI	∼650	AF130771, 2
15q22–qter	1	CYP1A2	cytochrome P450, subf. I, polyp. 2	50	2.5	HinfI	278	AF134063
15q26.1	1	FES[iii]	feline sarcoma virus homologue	58	2	—	510	AF130763
17q11.2	11	EVI2A	ecotropic viral int. site 2A	55	4	—	156	AF130762
17q11.2	11	NF1	neurofibromatosis I	58	2	—	380	AF130776
17q25	11	P4HB	prolyl-4 hydroxylase β	62	2	—	460	AF130777
17	11	MYL4	myosin light chain 4	58	2	—	682	AF130773
18p11.32	6	TS[iii]	thymidylate synthetase	55	1	—	539	AF130786
19q13	10	CKM[iii]	creatine kinase, muscle	58	1	—	819	AF130753
20pter–p12	22	PRNP	prion protein	55	1.5	—	191	AF134232
20q13.2	22	GNAS1	guanine nuc. binding protein	50	1.5	RsaI	324	AF134221
20q13.11	22	ADA	adenosine deaminase	50	1.5	—	∼1350	AF135790
21q22.3	26	ETS2	avian erythroblastosis virus onc. 2	55	2	HinfI	∼1000	AF134064
22q13.1	C	CYP2D[v]	cytochrome P450, subfamily IID	58	2	—	980	AF130756- 9
22q13.31–qter	C	ARSA	arylsulfatase A	58	2	—	247	AF130747
Xp11.21	X	ALAS2	Δ-aminolevulinate synthase	53	2	HaeIII	∼800	AF133200
Xq27.1–q27.2	X	F9	coagulation factor IX	55	2	—	453	AF133201
Xq28	X	BGN	biglycan	57	2	HinfI	∼710	AF135019, 0
Xq28	X	G6PD	glucose-6-phosphate dehydro.	55	2	HinfI	∼750	AF133202

[i] All primers used in this study were published by Lyons and coworkers (1997), with the following exceptions:

[ii] Multiple accession numbers indicated sequences obtained from the 5′ and 3′ ends of partially sequenced PCR products, or multiple highly homologous sequences most likely amplified from different syntenic isoforms of paralogous genes (see text).

[iii] Primers published by Venta and associates (1996).

[iv] The primers used to amplify equine IL1B were originally designed to amplify IL1A (see text).

[v] These primers amplify multiple equine fragments of different but highly homologous sequences (see text).

[vi] Amplifies a fragment of unknown sequence in addition to the equine SST gene (see text).

[vii] The forward primer used to amplify equine RB1 (5′=TTTGATATCGAAGGGTCTGAC-3′) was designed in this study and the reverse primer was as in Venta et al. (1996).

[viii] These primers amplify equine sequences lacking expected introns and therefore are thought to be horse pseudogenes from the respective loci.